Compare Summit Therapeutics Inc (SMMT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while T Rowe Price Group Inc trades at $113.73 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 2× Summit Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TROW | |
|---|---|---|
Market Cap | $12.06B | $24.26B |
Sector | Health | Financials |
52-Week High | $26.98 | $121.68 |
52-Week Low | $12.55 | $86.19 |
Enterprise Value | $11.39B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
T. Rowe Price (TROW) trades at $111.49, down 2.0% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 11.42, net income margin of 29.26%, and consistent dividend payments of $1.30 per share. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51 estimated, driven by higher assets under management and advisory revenue.
The outlook is mixed: strong profitability and a consensus price target of $112.17 offer upside, but bearish technicals and expense pressures pose risks. Investor sentiment is cautious with 63% analyst hold ratings, reflecting concerns over net outflows and market volatility impacting asset management fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
